Last updated: July 27, 2026
OFIRMEV (IV acetaminophen) clinical trials update, market analysis, and revenue projection
OFIRMEV (IV acetaminophen; active ingredient acetaminophen/paracetamol) has an established clinical position for short-term reduction of fever and postoperative pain in settings where oral dosing is not feasible. The product’s near-term commercial outlook is driven by: (1) U.S. hospital procurement cycles and formulary access, (2) conversion from oral/rectal acetaminophen to IV pathways for opioid-sparing perioperative care, and (3) competitive pressure from alternative IV analgesic and antipyretic options rather than from an immediate “clean-sheet” IV acetaminophen entrant.
No complete, drug-specific clinical-trials dataset (NCT numbers, sponsor arms, phase status, readouts) was provided for this request, so a precise “clinical trials update” limited to OFIRMEV trials cannot be generated from the information available in the prompt.
What clinical trials involve OFIRMEV (IV acetaminophen) and what is the current phase status?
Which trial types map to OFIRMEV’s label use
For IV acetaminophen, the highest-yield trial categories typically include:
- Postoperative pain trials comparing IV acetaminophen as part of multimodal analgesia vs control arms (placebo or standard care), with endpoints such as:
- time to meaningful pain reduction
- total opioid consumption
- patient-reported pain scores over defined intervals
- Fever/antipyretic trials in inpatient settings where oral intake is limited.
What to look for in “latest updates”
A clinically actionable update for OFIRMEV should include:
- Trial registry entries (NCT) with sponsor, phase, dosing schedule, comparators, and primary endpoint.
- Readout dates and whether the study reached statistical endpoints.
- Safety signals (hepatotoxicity risk management, infusion reaction rates, total daily dose adherence).
Clinical-trials update limitation
Because the request does not include a list of OFIRMEV-specific trial identifiers or an excerpt of recent registry/news items, this section cannot be populated with an accurate, numbered update (phase-by-phase, date-by-date) for OFIRMEV.
What is OFIRMEV’s market size and growth drivers in the U.S. hospital segment?
Demand drivers
Key demand drivers for IV acetaminophen in U.S. hospitals include:
- Perioperative opioid-sparing protocols that prefer IV non-opioid analgesics.
- Postoperative fast-track pathways (enhanced recovery after surgery, ERAS), where rapid analgesia and predictable dosing matter.
- Patient populations with swallowing issues or malabsorption where oral acetaminophen is impractical.
Procurement and adoption mechanics
- IV products are adopted through hospital pharmacy and therapeutics committee decisions, often tied to formulary tiering and bundled pathway protocols.
- Conversion tends to be incremental: hospitals expand IV acetaminophen use after demonstrating acceptable safety and reduced opioid metrics in internal audits.
Competitive intensity
Competition is usually measured against:
- Alternative IV analgesics (opioid formulations, NSAID-based strategies)
- Non-oral acetaminophen alternatives where available
- Standard-of-care shifts toward multimodal protocols using other agents
Without current sales data, shipment data, or competitor pricing/contracting details in the prompt, market sizing and year-by-year growth rates cannot be stated precisely.
How does OFIRMEV compare with oral and rectal acetaminophen and other IV analgesics?
Oral vs IV
- Oral acetaminophen offers lower acquisition cost and is used when patients can take oral meds.
- IV acetaminophen offers reliable administration in patients who cannot tolerate oral dosing and supports more consistent perioperative analgesia in early post-op hours.
IV vs opioid-sparing strategies
In ERAS-style pathways, IV acetaminophen functions as a baseline analgesic component intended to:
- reduce opioid requirement
- stabilize pain control during early recovery
- improve discharge readiness metrics tied to opioid minimization
Commercial implication
Where hospitals have strong opioid-sparing protocols, IV acetaminophen penetration tends to be higher.
When does OFIRMEV face exclusivity and patent expiration pressure?
What determines risk
For OFIRMEV, exclusivity and patent pressure in the U.S. would generally come from:
- Compound or composition-of-matter patents covering acetaminophen IV forms
- Formulation and method-of-use patents tied to dosing regimens and clinical endpoints
- Additional regulatory exclusivities (if any) that delay generic approval or narrow substitution pathways
Limitation
The prompt provides no OFIRMEV patent estate details, Orange Book listings, or filing/expiration dates. A correct, litigation-ready exclusivity timeline cannot be produced.
What is the Orange Book status of OFIRMEV and what generics are at risk?
What a complete Orange Book review would list
An Orange Book status summary normally includes:
- Listed patents for drug substance and drug product
- Expiration dates
- Orange Book submission types and listing status
Limitation
No Orange Book extract or patent listing data is included in the prompt, so a precise Orange Book table and generic entry risk assessment would be inaccurate if fabricated.
What generic entry risks exist for OFIRMEV under Paragraph IV?
Paragraph IV mechanics relevant to OFIRMEV
Paragraph IV challenges typically target:
- listed patents associated with the drug product, formulation, or method-of-use claims
- circumstances where a generic can carve around or invalidate specific patents
Limitation
No Paragraph IV case records, ANDA numbers, court filings, or settlement dates are provided in the prompt. A correct risk scenario cannot be produced without that case data.
How many patents cover OFIRMEV and how strong is the patent estate?
What “strength” analysis requires
A strength assessment usually aggregates:
- independent claim sets (composition, formulation, method-of-use)
- remaining term by jurisdiction
- infringement plausibility for generic ANDA labels
- known litigation outcomes or adverse claim constructions
Limitation
The prompt includes no OFIRMEV patent numbers, assignees, claim summaries, or remaining-life data.
What patent litigation affects OFIRMEV and what settlement terms are relevant?
What to capture in litigation updates
A litigation update should include:
- brand vs generic defendants
- district courts, filing and dismissal dates
- claim categories asserted
- settlement triggers (launch date carve-outs, payment terms, stipulations)
Limitation
No OFIRMEV litigation docket or settlement references are provided in the prompt.
What manufacturing and IP barriers affect generic or biosimilar-style substitution for OFIRMEV?
IV acetaminophen is a small-molecule. The practical substitution barriers usually concern:
- formulation and stability requirements for IV infusion quality
- process controls tied to impurity profiles and shelf-life
- clinical or labeling constraints that may reduce “therapeutic equivalence” substitution in practice
Limitation
Without OFIRMEV-specific formulation/process patent data and regulatory assessment information, this cannot be made specific.
OFIRMEV revenue projection: what is the forecast model and drivers?
Projection structure used for hospital-infusion brands
A defensible revenue projection for an established hospital infusion product generally uses:
- unit demand (doses or vials) driven by inpatient procedure volume and prescribing protocol penetration
- net price and rebate/contract effects
- share shift vs competing IV analgesics
- substitution risk from generics if/when competitive entry occurs
Limitation
The prompt provides no baseline revenues, dosage unit volumes, net price history, or competitor share. A numerical forecast would be non-auditable if created without the underlying dataset.
Key Takeaways
- OFIRMEV is positioned for inpatient postoperative pain and fever management when oral therapy is not appropriate.
- Commercial performance is most sensitive to hospital formulary access and opioid-sparing/perioperative pathways rather than to ongoing novelty-driven clinical trial dynamics.
- A fully sourced clinical trials update and a patent/Orange Book exclusivity and Paragraph IV risk assessment cannot be completed from the information in the prompt without introducing inaccuracies.
- A quantitative market size and revenue projection cannot be produced without baseline unit volume, net price, and regulatory/patent timeline inputs.
FAQs
- How is OFIRMEV typically used in ERAS postoperative pain protocols in U.S. hospitals?
- What safety considerations limit IV acetaminophen dosing in inpatient populations?
- How does hospital formulary placement impact OFIRMEV demand and contracting?
- What endpoints matter most in postoperative pain trials for IV acetaminophen?
- When do IV acetaminophen formulations face generic substitution under FDA equivalence frameworks?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. Search results for IV acetaminophen / OFIRMEV (acetaminophen injection). U.S. National Library of Medicine.
- FDA. Drug Trials Snapshots and related review materials for acetaminophen injection products. U.S. Food and Drug Administration.
